Paramagnetic relaxation enhancement (PRE) is the current strategy of choice for enhancing magnetic resonance imaging (MRI) contrast and for accelerating MRI acquisition schemes. Yet, debates regarding lanthanides' biocompatibility and PRE-effect on MRI signal quantification have raised the need for alternative strategies for relaxation enhancement. Herein, we show an approach for shortening the spin-lattice relaxation time (T1) of fluoride-based nanocrystals (NCs) that are used for in vivo 19F-MRI, by inducing crystal defects in their solid-crystal core. By utilizing a phosphate-based rather than a carboxylate-based capping ligand for the synthesis of CaF2 NCs, we were able to induce grain boundary defects in the NC lattice. The obtained defects led to a 10-fold shorter T1 of the NCs' fluorides. Such paramagnetic-free relaxation enhancement of CaF2 NCs, gained without affecting either their size or their colloidal characteristics, improved 4-fold the obtained 19F-MRI signal-to-noise ratio, allowing their use, in vivo, with enhanced hotspot MRI sensitivity.
Paramagnetic relaxation enhancement (PRE) is the current strategy of choice for enhancing magnetic resonance imaging (MRI) contrast and for accelerating MRI acquisition schemes. Yet, debates regarding lanthanides' biocompatibility and PRE-effect on MRI signal quantification have raised the need for alternative strategies for relaxation enhancement. Herein, we show an approach for shortening the spin-lattice relaxation time (T1) of fluoride-based nanocrystals (NCs) that are used for in vivo 19F-MRI, by inducing crystal defects in their solid-crystal core. By utilizing a phosphate-based rather than a carboxylate-based capping ligand for the synthesis of CaF2 NCs, we were able to induce grain boundary defects in the NC lattice. The obtained defects led to a 10-fold shorter T1 of the NCs' fluorides. Such paramagnetic-free relaxation enhancement of CaF2 NCs, gained without affecting either their size or their colloidal characteristics, improved 4-fold the obtained 19F-MRI signal-to-noise ratio, allowing their use, in vivo, with enhanced hotspot MRI sensitivity.
Entities:
Keywords:
19F-MRI; crystal defects; crystal engineering; in vivo MRI; nanocrystals; relaxation enhancement
The ability to design and control
the physical, chemical, electrical, optical, and magnetic properties
of small-sized molecular solids has greatly advanced the field of
nanocrystal (NC) engineering[1−4] contributing to the development of nanomedicine.[5] Among their various applications in nanomedicine,
NCs are widely used as imaging agents in optical[6] and photoacoustic imaging,[7] computed
tomography (CT),[8] and magnetic resonance
imaging (MRI),[9] and the ability to engineer
them in a desired manner has led to enhanced performance. Crystal
engineering has been used, for example, to alter quantum dots’
size,[10] shape,[11] and fluorescent properties.[12] Gold NCs
have been engineered to have controllable sizes[13] and shapes[14] as a means to enhance
their delivery and performance in both CT and photoacoustic imaging.[15] For MRI applications, metal oxide NCs have been
designed to have a multimetal core for enhanced sensitivity,[16] manganese-oxide core for positive contrast,[17] micrometer-size for single-cell visualization,[18] or extremely small-size for T1 contrast
enhancement.[19]Nanosized inorganic
fluoride (specifically, CaF2)[20] NCs have been recently designed and implemented
as imaging tracers benefiting from the advantageous background-free 19F-MRI.[21−25] Their small size (<10 nm) and their inorganic solid core make
them a unique category of 19F-MRI tracers, distinct from
the extensively developed and frequently used perfluorocarbon (PFC)
nanoemulsions,[22,23] with the potential to be further
developed for applications where small-sized NCs and tunable morphologies
are essential.[26,27] However, one of the main limitations
of CaF2 NCs as 19F-MRI agents is their long
spin–lattice relaxation time T1 (>10 s), which
prolongs
the time of data acquisition when signal averaging is needed for an
improved signal-to-noise ratio (SNR). One potential strategy for efficient
shortening of the T1 of the fluorine-19 content is to induce
paramagnetic relaxation enhancement (PRE), which was efficiently demonstrated
for large-sized PFC nanoemulsions,[28−31] resulting in several-fold enhanced
sensitivity of 19F-MRI. Nevertheless, alternatives for
paramagnetic dopants need to be considered, not only to address recently
raised concerns of lanthanide biocompatibility[32,33] but also to allow robust quantification of the 19F-tracer
distribution from the 19F-MR signal, as such quantification
has been shown to be far from straightforward in solid-materials in
the presence of dopants with a strong PRE effect.[34] Herein, we propose an alternative to the commonly used
PRE approach and show that synthetic induction of crystal defects
in small-sized CaF2 NCs significantly shortens the T1 relaxation time of the fluoride within the NC, allowing improved in vivo19F-MRI sensitivity.The area of
surface chemistry bridges the gap between NCs’
fabrication and their properties and has been exploited for strategizing
synthetic routes. One approach is to utilize the binding affinities
of ligands to the surface of the NCs and their precursors in order
to manipulate the morphology of nanomaterials.[35] Based on the rationale that Ca2+ (a CaF2 precursor) binds more strongly to phosphate groups than to
carboxylate groups,[36] CaF2 NCs
were synthesized with two different ligands, namely, oleic acid (OA, Figure a) and oleyl phosphate
(OP, Figure b). Note
that except for their headgroup, OA and OP share identical organic
tails, allowing a similar outer coating, essential for their colloidal
stability. Indeed, both OA-CaF2 and OP-CaF2 fabrications
result in a similar small core size (8.3 ± 0.8 nm and 8.0 ±
1.3 nm, respectively, Figure a–c) and comparable colloidal diameter (10.5 ±
3.0 nm and 10.4 ± 2.9 nm, respectively, Figure d).
Figure 1
Characterization of OA-CaF2 and OP-CaF2 NCs:
The molecular structures of the oleic acid (OA, light blue) and the
oleyl phosphate (OP, pink) ligands used to synthesize OA-CaF2 (a) and OP-CaF2 (b), respectively, and representative
TEM images of the NCs (scale bar 50 nm). (c) Average diameter of OA-CaF2 (8.3 ± 0.8 nm) and OP-CaF2 NCs (8.0 ±
1.3 nm) as obtained from the TEM images. (d) The colloidal diameter
of dispersed OA-CaF2 (10.5 ± 3.0 nm) and OP-CaF2 NCs (10.4 ± 2.9 nm) as obtained from DLS measurements.
Characterization of OA-CaF2 and OP-CaF2 NCs:
The molecular structures of the oleic acid (OA, light blue) and the
oleyl phosphate (OP, pink) ligands used to synthesize OA-CaF2 (a) and OP-CaF2 (b), respectively, and representative
TEM images of the NCs (scale bar 50 nm). (c) Average diameter of OA-CaF2 (8.3 ± 0.8 nm) and OP-CaF2 NCs (8.0 ±
1.3 nm) as obtained from the TEM images. (d) The colloidal diameter
of dispersed OA-CaF2 (10.5 ± 3.0 nm) and OP-CaF2 NCs (10.4 ± 2.9 nm) as obtained from DLS measurements.High-resolution TEM (HR-TEM) analysis of the crystal
structure
of OP-CaF2 and OA-CaF2 at the atomic level revealed
a remarkable difference in the crystal architecture of the two types
of NCs (Figure a and Figure b). While OA-CaF2 NCs exhibited a well-ordered, highly crystalline lattice
(Figure a), OP-CaF2 NCs featured clear crystal defects, i.e., grain boundaries
(Figure b). This observation
was further validated by powder X-ray diffraction (XRD) measurements
of dried samples of OA-CaF2 (Figure c) and OP-CaF2 (Figure d) NCs, showing wider XRD patterns
for the disordered OP-CaF2 NCs, as demonstrated for other
inorganic materials.[37] An additional indication
for the polycrystallinity of OP-CaF2 NCs was obtained using
Raman spectroscopy (Figure S1); both line
broadening and Raman shifts were observed for OP-CaF2 NCs
(as compared to powders of commercial CaF2 and OA-CaF2), which can be assigned to a smaller grain size within the
polycrystalline material. We attribute the crystallographic differences
between OP-CaF2 and OA-CaF2 NCs to different
growth paths mediated by the nature of the surface ligands present
during the synthesis.[38,39]
Figure 2
Characterization of OA crystalline features
of OA-CaF2 and OP-CaF2 NCs. (a, b) HR-TEM image
(scale bar 10 nm,
in inset 5 nm) of (a) OA-CaF2 and (b) OP-CaF2 NCs. (c, d) Powder XRD patterns of dry samples of (c) OA-CaF2 and (d) OP-CaF2 NCs.
Characterization of OA crystalline features
of OA-CaF2 and OP-CaF2 NCs. (a, b) HR-TEM image
(scale bar 10 nm,
in inset 5 nm) of (a) OA-CaF2 and (b) OP-CaF2 NCs. (c, d) Powder XRD patterns of dry samples of (c) OA-CaF2 and (d) OP-CaF2 NCs.It was previously shown that crystallographic defects, induced
by mechanical stress of large-size CaF2 crystals, may facilitate
element mobility and enhance dipolar interaction, which could induce
T1 shortening[40,41] without the use of
paramagnetic elements. Encouraged by these studies and with the vision
of using CaF2 NCs as nanosized tracers for 19F-MRI applications, we studied the effect of their crystal properties
on their 19F-NMR characteristics using a liquid-state high-resolution 19F-NMR setup. Notably, both dispersed OA-CaF2 and
OP-CaF2 NCs produced similar 19F-NMR spectra
(Figure S2), with a typical CaF2 peak at −109 ppm. Interestingly and importantly for their
use as nanotracers in 19F-MRI applications, we found a
dramatic difference in the T1 values of the 19F fluoride signal in the colloidal CaF2 NCs (Figure S3a,b), a result of the pronounced grain
boundary defects in OP-CaF2 NCs (Figure b). This 10-fold reduction in T1 should allow significant improvement in the sensitivity of 19F-MRI studies when using OP-CaF2 compared to OA-CaF2 NCs. Note that the short T2 that is characteristic
to nanofluorides was similar in both fabrications (Figure S3c,d); nevertheless, such limitation could be overcome
by using an MRI scheme such as ultrashort TE (UTE) or zero TE (ZTE),
found to be applicable to both nanofluorides[20] and paramagnetic PFCs.[29]Next,
we assessed whether the significant T1 relaxation
enhancement observed for polycrystalline nanofluorides (OP-CaF2) as compared to crystalline nanofluorides (OA-CaF2) in organic solvents could be translatable to improved 19F-MRI sensitivity in vivo. For that purpose, both
fabrications were transferred from an organic solvent (cyclohexane)
to an aqueous solution by incorporating phospholipids (PLs) into the
hydrophobic tails of their capping ligands and stabilizing these colloids
with cholesterol content and polyethylene-glycol-modified phospholipids
(Figure a and Figure S4). The resultant colloids endowed both
PL-OA-CaF2 and PL-OP-CaF2 NCs with water solubility
and colloidal stability characteristics suitable for in vivo19F-MRI tracers (Figure S5). The stability of the water dispersed NCs in aqueous media was
studied for 40 days by both DLS measurements and high-resolution 19F-NMR spectroscopy (Figure S7),
showing their long-term stability and resistance to degradation when
stored for future uses. It is important to mention here that the 10-fold
difference in the T1 values of the two types of nanofluorides
was preserved for water-dispersed NCs, with 11 ± 0.2 s for PL-OA-CaF2 and 1 ± 0.2 s for PL-OP-CaF2 NCs (Figure d and Figure S6).
Figure 3
High-resolution 19F-NMR properties
of CaF2 NCs in water. (a) Schematic representation of phase
transfer (from
organic solvent to water) via ligand incorporation of phospholipids
(molecular structures in Figure S4). 19F-NMR spectra of (b) PL-OA-CaF2 (light-blue) and
(c) PL-OP-CaF2 (pink) dispersed in water. (d) 19F-T1-relaxation times for PL-OA-CaF2 (11.0
± 0.2 s) and PL-OP-CaF2 NCs (1.2 ± 0.2 s).
High-resolution 19F-NMR properties
of CaF2 NCs in water. (a) Schematic representation of phase
transfer (from
organic solvent to water) via ligand incorporation of phospholipids
(molecular structures in Figure S4). 19F-NMR spectra of (b) PL-OA-CaF2 (light-blue) and
(c) PL-OP-CaF2 (pink) dispersed in water. (d) 19F-T1-relaxation times for PL-OA-CaF2 (11.0
± 0.2 s) and PL-OP-CaF2 NCs (1.2 ± 0.2 s).In order to quantify the improvement in 19F-MRI sensitivity
upon T1 shortening, a phantom composed of two tubes with
the same 19F concentration, one containing water-dispersed
PL-OP-CaF2 NCs and the other containing water-dispersed
PL-OA-CaF2 NCs, was studied (Figure a). Indeed, a four times higher SNR was obtained
in 19F-MRI for the tube containing the PL-OP-CaF2 as compared to that of PL-OA-CaF2 NCs (Figure b,c), acquired with a UTE sequence
to detect the 19F-MR signal of the fluorides in the NCs.[20] The 10-fold shorter T1 of the fluorides
in PL-OP-CaF2 allowed us to shorten dramatically the repetition
time (TR) and, thus, to increase the number of signal averages for
a given time of acquisition or to shorten the total scan time for
a given number of signal averages. Note that in order to obtain a
comparable 19F-MRI SNR from the crystalline PL-OA-CaF2 NCs, a much longer TR was needed, and consequently, a more
than 1 h acquisition time to allow the same number of signal averages
would be required (compared to the 6.5 min needed for TR = 4.2 ms, Figure b,c). In order to
obtain a comparable SNR of the two types of NCs using a single-scan
acquisition, a ten-time longer acquisition was needed for PL-OA-CaF2 NCs as compared to that required for PL-OP-CaF2 NCs (Figure S8).
Figure 4
19F-MRI of
CaF2 NCs. (a) 1H-MRI
and (b) 19F-MRI of a phantom composed of two tubes containing
either PL-OA-CaF2 or PL-OP-CaF2 NCs. For 19F-MRI data, a 3D-UTE sequence was used. (c) Calculated SNR
values for of PL-OA-CaF2 (27 ± 3) and of PL-OP-CaF2 (115 ± 16) as measured from the 19F-MRI in
b. SNR and (d) 1H-MRI and (e) 19F-MRI of a phantom
composed of five tubes containing different concentrations of PL-OP-CaF2 (i.e., total 19F): 100, 50, 15, 10, and 5 mM (1–5,
respectively, in d). (f) SNR as a function of 19F atoms
per voxel (4 mm3), as obtained from the data in e.
19F-MRI of
CaF2 NCs. (a) 1H-MRI
and (b) 19F-MRI of a phantom composed of two tubes containing
either PL-OA-CaF2 or PL-OP-CaF2 NCs. For 19F-MRI data, a 3D-UTE sequence was used. (c) Calculated SNR
values for of PL-OA-CaF2 (27 ± 3) and of PL-OP-CaF2 (115 ± 16) as measured from the 19F-MRI in
b. SNR and (d) 1H-MRI and (e) 19F-MRI of a phantom
composed of five tubes containing different concentrations of PL-OP-CaF2 (i.e., total 19F): 100, 50, 15, 10, and 5 mM (1–5,
respectively, in d). (f) SNR as a function of 19F atoms
per voxel (4 mm3), as obtained from the data in e.To quantify the improved sensitivity in 19F-MRI experiments
and to examine the detectability level of PL-OP-CaF2 NCs,
a series of tubes containing a range of concentrations was prepared
and studied (Figure d–f). Notably, by shortening the T1 values of the
nanofluorides by one order of magnitude, we were able to detect low 19F concentrations down to 5 mM, 10 times lower than the detectability
level of the highly crystalline CaF2.[20] For example, an SNR of 28 in the 19F-MRI of
the studied phantom was obtained with a 5 mM 19F-concentration
(equivalent to 1.2 × 1016 fluorine spins) with a voxel
size of 4 mm3, a level of 19F-MRI detectability
comparable to that of the commonly used PFC nanoemulsions.[42] The very long T2 values of PFCs,
however, allows us to acquire their 19F-MRI data using
multi-echo-based schemes (i.e., RARE or FSE) and thus provide them
with essential improved sensitivity for a given time of data acquisition
when directly compared to PL-OP-CaF2 NCs (Figure S9 and Table S1). Nevertheless, it is important to
mention that while the short T2 limitation of PL-OP-CaF2 could be overcome by using a UTE-MRI scheme, such sequences
are still in their infancy. Therefore, we expect that more advanced
UTE protocols that allow multi-echo readouts[43] and those based on compressed sensing[44] should further improve the SNR/time-unit of 19F-MRI data
that is based on nanofluorides even at their given short T2 values.Moreover, and very importantly, the fact that PL-OP-CaF2 NCs and PFC-based emulsions differ in size by one order of
magnitude
(i.e., ∼10 nm for CaF2 and ∼100 nm for PFCs, Figure S10a) show that each of the nanoformulations
could be used and may be more applicable for different approaches
due to their expected different biodistribution, clearance profiles,
and accessibility to a desired target. Showing that the chemical shift
in the 19F-NMR of PFC-based nanoemulsions (−91 ppm
for VS1000) differs from that of CaF2 NCs (−109
ppm) by almost 20 ppm demonstrates the potential of using the two
nanofabrications in future “multicolor” 19F-MRI studies (Figure S10b–h).
Thus, capitalizing on this multiplexing feature, given their very
different hydrodynamic diameter (Figure S10a), may open new opportunities to combine these nanoformulations for
noninvasive multiplexed imaging, for example, in studies where the
size of the imaging agent is essential.Finally, to evaluate
the potential of PL-OP-CaF2 NCs
as imaging tracers for in vivo 19F-MRI applications and
to determine the gain in sensitivity, noninvasively, in a live intact
subject, both designed NCs were intramuscularly injected into mouse
legs (Figure a) after
determining their cytotoxicity profile using three different cell-based
assays, namely, (i) CCK-8 assay (Figure S11), (ii) MTT assay (Figure S12), and (iii) LDH-cytotoxicity
assay (Figure S13). A localized 19F-NMR spectrum of each leg showed a comparable intensity of the CaF2 peak (−109 ppm; Figure b,c and Figure S14) when
the acquisition parameters were adjusted to the T1 properties
of each formulation, indicating the comparable CaF2 concentration
in the two injection sites. Significantly, although the same fluoride
content was confirmed for both injections, a notable 19F-MRI signal was picked up only in the leg injected with PL-OP-CaF2 NCs (Figure d,e), which could be displayed as a “hotspot” map overlaid
on anatomical high-resolution 1H-MRI (Figure f). These results demonstrate
that, while avoiding the use of paramagnetic elements and without
introducing the PRE-effect for shortening T1 values, we
were able to extensively enhance the longitudinal relaxation rates
of small-sized fluoride-NCs to improve 19F-MRI performances.
Figure 5
In vivo 19F-NMR and 19F-MRI of injected PL-OA-CaF2 and PL-OP-CaF2 NCs. (a) Scheme of the injection
setup. (b) 19F-ISIS spectra acquired from the right leg
(PL-OP- CaF2 injection) using TR = 3 s and (c) from the
left leg (PL-OA-CaF2 injection) using TR = 30 s. (d) 1H-MRI, (e) 19F-MRI (acquired with a 3D-UTE sequence),
and (f) 19F-MRI shown as a pseudocolor map overlaid on
the anatomical 1H-MR image of a live mouse.
In vivo 19F-NMR and 19F-MRI of injected PL-OA-CaF2 and PL-OP-CaF2 NCs. (a) Scheme of the injection
setup. (b) 19F-ISIS spectra acquired from the right leg
(PL-OP- CaF2 injection) using TR = 3 s and (c) from the
left leg (PL-OA-CaF2 injection) using TR = 30 s. (d) 1H-MRI, (e) 19F-MRI (acquired with a 3D-UTE sequence),
and (f) 19F-MRI shown as a pseudocolor map overlaid on
the anatomical 1H-MR image of a live mouse.In summary, we propose here a paramagnetic-free approach
for T1-relaxation enhancement as an alternative to the
extensively
used PRE effect, avoiding the need for paramagnetic elements in MRI
studies. We demonstrate that inducing defects in small-sized nanofluorides
allows us to shorten the T1 of their fluoride content by
10-fold, resulting in a 4-fold increase in the SNR of 19F-MRI studies at a given scan time. While PRE has been at the core
of many MRI studies for many decades,[45] allowing researchers to shorten both transverse[46] and longitudinal[47] relaxation
times for enhanced image contrast, it has been exploited also to shorten
the T1 values of fluorinated materials[29] for improved SNR in 19F-MRI studies. Our demonstration
that controlling the synthetic conditions of fluoride-based NCs and
engineering crystal defects (specifically, grain boundaries) to shorten
the T1 of nanofluorides, which together with their manifested
in vivo capabilities, offers a novel strategy for fabricating paramagnetic-free
nanotracers for in vivo 19F MRI studies. While there is
still a scope for shortening the T1 of nanoflurides, the
presented approach for nanocrystalline-defects relaxation enhancement
(NDRE) should be further developed by using other strategies to rationalize
architecture-relaxation relationships in NCs that are proposed as
imaging nanotracers for “hotspot” MRI, even beyond nanofluorides.
Authors: X Michalet; F F Pinaud; L A Bentolila; J M Tsay; S Doose; J J Li; G Sundaresan; A M Wu; S S Gambhir; S Weiss Journal: Science Date: 2005-01-28 Impact factor: 47.728
Authors: Peter J Niedbalski; Alexander S Cochran; Teckla G Akinyi; Robert P Thomen; Elizabeth M Fugate; Diana M Lindquist; Ronald G Pratt; Zackary I Cleveland Journal: NMR Biomed Date: 2020-04-14 Impact factor: 4.044
Authors: Sonia Waiczies; Jason M Millward; Ludger Starke; Paula Ramos Delgado; Till Huelnhagen; Christian Prinz; Daniel Marek; Didier Wecker; Ralph Wissmann; Stefan P Koch; Philipp Boehm-Sturm; Helmar Waiczies; Thoralf Niendorf; Andreas Pohlmann Journal: Sci Rep Date: 2017-08-29 Impact factor: 4.379